Moderna, Inc. $MRNA Shares Sold by BDF Gestion

Key Points

• BDF Gestion cut its Moderna stake by 66.3% in the third quarter, selling 11,523 shares and retaining 5,847 shares valued at approximately $1.13 million.
• Institutional investors own 75.33% of Moderna, while several smaller firms initiated or increased positions during the quarter.
• Moderna shares opened at $226.89, near their 12-month high, although analysts maintained a consensus “Hold” rating with an average price target of $101.45. Upcoming melanoma vaccine data and broader oncology catalysts could influence investor sentiment.

BDF Gestion lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 66.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,847 shares of the company's stock after selling 11,523 shares during the period. BDF Gestion's holdings in Moderna were worth $1,126,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MRNA. Western Pacific Wealth Management LP bought a new stake in shares of Moderna in the third quarter worth approximately $29,000. Fortitude Family Office LLC raised its holdings in shares of Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company's stock valued at $43,000 after purchasing an additional 77 shares during the last quarter. Allied Private Wealth LLC purchased a new position in shares of Moderna during the second quarter valued at approximately $30,000. Archer Investment Corp purchased a new position in shares of Moderna during the second quarter valued at approximately $36,000. Finally, Canton Hathaway LLC bought a new position in Moderna during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $226.89 on Tuesday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $242.29. The firm has a market capitalization of $90.58 billion, a price-to-earnings ratio of -28.40 and a beta of 1.09. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $160.00 and a 200 day moving average of $92.42.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the firm earned ($2.13) earnings per share. The company's quarterly revenue was up 2.1% on a year-over-year basis. On average, research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Higher price targets: Oddo BHF raised its Moderna price target to $251 from $170, following a broader improvement in sentiment toward the company’s pipeline. BofA also recently increased its target, reinforcing the bullish outlook. Oddo BHF Adjusts Moderna Price Target to $251 From $170
• Positive Sentiment: Investors are positioning ahead of melanoma data: Moderna is expected to provide detailed Phase 3 data this Saturday for its personalized cancer vaccine, developed with Merck. Favorable results could strengthen the case for a major oncology growth opportunity beyond COVID-19 vaccines. What's Going On With Moderna Stock Monday?
• Positive Sentiment: Upcoming ESMO visibility: Merck/Moderna’s oncology program is among the key topics expected to attract attention at ESMO 2026, potentially increasing investor focus on Moderna’s cancer pipeline and clinical catalysts. Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
• Positive Sentiment: Index inclusion and AI-driven healthcare theme: Moderna’s addition to the Nasdaq-100 may support institutional demand and visibility. Separately, analysts are highlighting the company as a potential beneficiary of “biointelligence,” including data-driven drug development and personalized therapies. Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
• Neutral Sentiment: Biotech sector interest: Moderna appeared on a broader list of biotech stocks to watch, but the item provided no major company-specific development. Biotech Stocks To Watch Now - October 15th
• Negative Sentiment: Insider selling: Moderna’s president sold roughly $8.4 million and $8.6 million worth of shares in separate reported transactions. The sales may weigh on sentiment, particularly after an earlier report linked insider selling to a sharp decline in the stock. Moderna President Sells $8,373,539.52 in Stock Insider Selling: Moderna President Sells $8,640,084.40 in Stock

Analysts Set New Price Targets

MRNA has been the topic of several research reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Moderna in a report on Friday, August 28th. They issued a "hold" rating and a $125.00 target price on the stock. Rothschild & Co Redburn lowered shares of Moderna from a "neutral" rating to a "sell" rating and boosted their target price for the company from $40.00 to $81.00 in a research note on Thursday, September 3rd. UBS Group reiterated a "neutral" rating on shares of Moderna in a research note on Tuesday, September 22nd. Barclays increased their price target on Moderna from $48.00 to $125.00 and gave the company an "equal weight" rating in a report on Monday, August 24th. Finally, Royal Bank Of Canada restated a "sector perform" rating and issued a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $101.45.

Insider Activity

In other news, President Stephen Hoge sold 39,145 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares of the company's stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company's stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 in the last 90 days. Company insiders own 10.80% of the company's stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.